Litcius/Paper detail

Assessing the risk of dupilumab use for atopic dermatitis during the COVID-19 pandemic

Donovan G. Kearns, S. K. Uppal, Vipawee S. Chat, Jashin J. Wu

2020Journal of the American Academy of Dermatology17 citationsDOIOpen Access PDF

Topics & Concepts

MedicinePandemicCoronavirus disease 2019 (COVID-19)DupilumabAtopic dermatitisSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakCoronavirusDermatologyIntensive care medicineDiseaseVirologyInfectious disease (medical specialty)Internal medicineOutbreakDermatology and Skin DiseasesAllergic Rhinitis and SensitizationContact Dermatitis and Allergies
Assessing the risk of dupilumab use for atopic dermatitis during the COVID-19 pandemic | Litcius